NU 0412: A PHASE I/II STUDY OF OXALIPLATIN, 5-FLUOROURACIL AND DOCETAXEL

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。受试者被要求参加这项研究是因为他/她患有无法通过手术或放射治疗治愈的癌症。此外，他/她的癌症要么在化疗期间生长，要么在接受普通化疗治疗期间可能生长。该研究涉及化疗药物的治疗：奥沙利铂、5-氟尿嘧啶和多西紫杉醇（泰索帝）。这些药物已被美国食品和药物管理局（FDA）批准用于治疗多种癌症；然而，这种组合被认为是实验性的。同时使用这三种化疗药物时的推荐剂量和时间表尚未确定。本研究的目的是评价奥沙利铂、5-氟尿嘧啶和多西紫杉醇联合治疗的效果（好与坏）。此外，该研究旨在确定多西紫杉醇与奥沙利铂和5-氟尿嘧啶合用的最高剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The subject is being asked to participate in this research study because he/she has cancer which is not curable by surgery or radiation therapy. In addition, his/her cancer has either grown while on chemotherapy or is likely to grow while on common chemotherapy treatments. This study involves treatment with the chemotherapy drugs: oxaliplatin, 5-fluorouracil, and docetaxel (Taxotere). These drugs have been approved by the Food and Drug Administration (FDA) for the treatment of a wide variety of cancers; however, the combination is considered experimental. The recommended dose and schedule has yet to be determined when using all three chemotherapy drugs together. The purpose of this research study is to evaluate the effects (good and bad) of the combination of oxaliplatin, 5-fluorouracil, and docetaxel. In addition, the study is to determine the highest dose of docetaxel that can be given safely with oxaliplatin and 5-fluorouracil.